The role of advanced lipid testing in clinical practice.
The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines recommend assessing an individual's cardiovascular (CV) risk from the Framingham risk score; however, the Framingham risk score may underestimate coronary heart disease (CHD) risk. Current guidelines have identified some emerging lipid risk factors that can be measured by several commercially available advanced cholesterol tests. These emerging lipid risk factors are meant to supplement the Framingham risk score to help the clinician to better assess CV risk. Although advanced lipid testing cannot be recommended for routine screening, it may be of value in individuals with a family history of premature CHD, postmenopausal women, and individuals at intermediate risk for CHD, especially if they are near the boundary of being at high risk. This review examines the role of advanced lipid testing in clinical practice.
Karalis
Dean G
DG
Drexel University College of Medicine, Philadelphia, PA 19107, USA. dgk25@drexel.edu
D003327:Coronary Disease / Q000097:blood*; D006403:Hematologic Tests / Q000592:standards; D006801:Humans; D008055:Lipids / Q000097:blood*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012307:Risk Factors
D008055:Lipids